This online format will facil- itate rapid updates as new evidence emerges. abstract www.kidney-international.org Introduction The original KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease in the chronic kidney disease (CKD) population not receiving dialysis was published in 2012. Since then, completion of the SPRINT trial and the revision of blood pressure (BP) guide- lines by many guideline task forces around the world have prompted the re-examination of the KDIGO 2012 Guideline for the Management of Blood Pressure. Upon invitation by the KDIGO Executive Committee, a Work Group consisting of a subset of the members of the original guideline panel and some new members was formed in 2018. The Cochrane Kidney and Transplant group from Australia was selected as the Evidence Review Team (ERT) for the update, and a new online publishing software, MAGICapp, was introduced with the aim to create a living guideline that is consistently kept up-to-date. A Controversies Conference was held in Edinburgh in September 2017 to help better identify the emerging evidence, ongoing controversies, and unsettled questions in relation to BP management in CKD. The conclusions from this confer- ence helped to frame the Scope of Work for the Guideline update. It was decided that since the de nition, management, and nuances of high BP in the maintenance dialysis popula- tion are signi cantly different from those in the CKD popu- lation not receiving dialysis, the Work Group should con ne its purview to the latter population in keeping with the 2012 guideline. The chapters from the original guidelines have been reor- ganized. The section on pharmacologic agents in the original chapter on Lifestyle and pharmacologic treatments for lowering blood pressure in CKD ND patients has been signi cantly streamlined and separated. 